In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Plexxikon, Wyeth ally in developing diabetes treatments
18 Jul 2005
Wyeth Pharmaceuticals licensed exclusive development and marketing rights to Plexxikon's (small-molecule drug discovery) lead candidate PLX204 and other small-molecules that target peroxisome proliferator-activated receptors (PPARs) to treat metabolic disorders such as Type II diabetes.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?